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Abbreviations:  
BBB, blood-brain barrier; MS, multiple sclerosis; miRNAs, microRNAs; CNS, central 
nervous system; EAE, experimental autoimmune encephalomyelitis; IJC, interendothelial 
junctional complex; MS-NAWM, MS normal appearing white matter; LPS, 
lipopolysaccharide; BEC, brain endothelial cell; ECM, extracellular matrix; OS, onset of 
signs; APP, acute phase paralysis; LCM, laser capture microdissection; hCMEC/D3, human 
cerebral microvascular endothelial cell line; PFA, paraformaldehyde; ISH, in situ 
hybridization; DOCK-1, dedicator of cytokinesis 1; SDCBP, syntenin-1; PALLD, palladin; 
ITGAV, integrin alpha-V; ANXA-2, annexin-2; CLDN-1, claudin-1; PRNP, prion protein; 
SSC, saline sodium citrate; PBS, phosphate buffer saline; 3’UTR, 3’untranslated region; RT, 
room temperature; SEM, standard error of the mean. 
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Abstract 
Blood-brain barrier (BBB) dysfunction is a hallmark of neurological conditions such as 
multiple sclerosis (MS) and stroke. However, the molecular mechanisms underlying 
neurovascular dysfunction during BBB breakdown remain elusive. MicroRNAs (miRNAs) 
have recently emerged as key regulators of pathogenic responses although their role in central 
nervous system (CNS) microvascular disorders is largely unknown. Here, we have identified 
miR-155 as a critical miRNA in neuroinflammation at the BBB. MiR-155 is expressed at the 
neurovascular unit of individuals with MS and of mice with experimental autoimmune 
encephalomyelitis (EAE). In mice, loss of miR-155 reduced CNS extravasation of systemic 
tracers both in EAE and in an acute systemic inflammation model induced by 
lipopolysaccharide. In cultured human brain endothelium, miR-155 was strongly and rapidly 
upregulated by inflammatory cytokines. MiR-155 upregulation mimicked cytokine-induced 
alterations in junctional organization and permeability whereas inhibition of endogenous 
miR-155 partially prevented cytokine-induced increase in permeability. Furthermore, miR-
155 modulated brain endothelial barrier function by targeting not only cell-cell complex 
molecules such as annexin-2 and claudin-1 but also focal adhesion components such as 
DOCK-1 and syntenin-1. We propose brain endothelial miR-155 as a negative regulator of 
blood-brain barrier function that may constitute a novel therapeutic target for central nervous 
system neuroinflammatory disorders.  
 
Key Words: 
Multiple sclerosis, neurovascular dysfunction, junctional complex molecules, focal adhesion.
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Introduction  
In neuroinflammation, stroke and some neurodegenerative diseases such as multiple sclerosis 
(MS), the permeability of the blood-brain barrier (BBB) increases, contributing to the onset 
and/or worsening of the disease. Although the mechanisms are not completely understood, it 
is thought to involve disassembly of interendothelial junctional complex (IJC) and integrin 
focal adhesion complexes (1-3), probably as a result of altered expression of tight junctional 
proteins in response to pro-inflammatory cytokines such as TNFα and IFNγ (4-6). In vitro 
these cytokines increase brain endothelial cell (BEC) permeability by modulation of gene 
expression at transcriptional and/or post-transcriptional levels (3, 5, 7) . Recently, 
microRNAs (miRNAs) have emerged as important additional post-transcriptional regulators 
of gene expression which can silence target genes by translation inhibition, mRNA decay or 
both (8). Indeed, miRNAs might constitute an important regulatory control of the brain 
endothelial response by fine-tuning several of the cellular and molecular processes triggered 
by inflammatory mediators (7). Furthermore, deregulated miRNA levels have been 
demonstrated in several pathologies although their role in the pathogenesis of central nervous 
system (CNS) inflammatory disorders remains to be fully elucidated.  
 
One of the best-characterized miRNAs is miR-155, which has pleotropic functions in 
inflammation, autoimmunity and cell plasticity (9-11). Thus far, miR-155 has been shown to 
induce a decrease in the expression levels of multiple identified transcripts but the effect is 
modest, characteristic of fine-tuning regulation (12, 13). Moreover, endothelial miR-155 has 
been shown to regulate the expression of endothelial nitric oxide synthase during 
inflammatory stimuli (14). In the context of neuroinflammation, miR-155 has been shown to 
be one of the most highly elevated miRNAs in acute MS lesions (15). At a functional level, 
loss of miR-155 partially protects mice from the development of experimental allergic 
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encephalomyelitis (EAE), a model of MS (10, 16). This correlates with its actions in 
promoting differentiation of TH17 cells (17), inhibiting TH2-type immune responses and 
mediating activation of T cells, mononuclear phagocytes and dendritic cells (10, 18, 19). 
However, since the symptoms of EAE are related to increased BBB permeability, it is equally 
possible that miR-155 is acting directly in BECs to modulate BBB function.  
 
In this study, we demonstrated altered levels of miR-155 at the neurovascular unit in MS 
brains and EAE spinal cords. MiR-155-/- mice showed lower levels of BBB leakage in EAE 
and an acute model of systemic inflammation. Mechanistically, we found that miR-155 
regulated human brain endothelial permeability by targeting molecules involved in cell-to-
cell, annexin-2 and claudin-1, and cell-to-extracellular matrix (ECM) interactions, DOCK-1 
and syntenin-1. Our results demonstrate that brain endothelial miR-155 negatively regulates 
BBB function thereby constituting a novel therapeutic target for MS and other 
neuroinflammatory conditions associated with BBB breakdown. 
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Materials and methods  
Human and animal tissues. Human brain samples of MS patients and control patients without 
neurological diseases were obtained from the UK Multiple Sclerosis Tissue Bank (Imperial 
College London, London, UK). Adult male and female (10–12 weeks) Biozzi ABH mice 
were purchased from Harlan UK Ltd (Bicester, UK) whereas miR-155-/- mice and miR-155+/+ 
C57BL/6 mice were from Jackson Laboratory (Kent, UK). All procedures were approved 
following ethical review processes in accordance with the Animals (Scientific Procedures) 
Act 1986 of the UK government and the ARRIVE guidelines (20).  
 
Induction of experimental autoimmune encephalomyelitis. EAE was induced in Biozzi ABH 
mice with 1mg freeze-dried mouse spinal cord homogenate in Freund’s adjuvant 
supplemented with 60mg Mycobacterium tuberculosis H37Ra and Mycobacterium butyricum 
as previously described (20). In miR-155-/- or miR-155+/+ C57BL/6 (B6.Cg-miR-
155tm1.1Rsky/J) mice, EAE was induced using Hooke Kit™ (EK-2110) MOG35-55/CFA 
Emulsion PTX following the manufacturer’s protocols (Hooke Laboratories, Lawrence, MA, 
USA). Animals were monitored daily to assess the development of relapsing–remitting 
paralysis and scored as follows: 0=normal; 1=limp tail; 2=impaired righting reflex; 3=hind-
limb paresis and 4=complete hind-limb paralysis (20). The EAE status were based on 
paralytic clinical disease and weight loss/gain as follows: Onset of signs (OS), clinical score 
1 with weight loss sampled on day 15 post-induction; Acute phase paralysis (APP), clinical 
score 3.5-4 and losing weight on day 17; Recovery, clinical score 3.5 to 1 with weight gain 
on day 20; Remission one, clinical score 0.5 with weight gain on day 28 post-induction; 
Chronic, clinical score 3.5 with stable weight during remission from attack 3 months 
following induction (20). 
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Laser capture microdissection and isolation of microvessels. Laser capture microdissection 
(LCM) was used to collect enriched brain endothelium RNA using a rapid staining protocol 
described in the Supplementary Methods online (21). 
Microvessels were isolated from the mouse spinal cords as previously described with 
modification (22). Briefly, EAE or normal ABH mice were perfused with Hank’s balanced 
solution containing 0.5% BSA to rinse out the blood, then the spinal cords were flushed out. 
The spinal cords were digested with collagenase and dispase (1mg/ml) at 37oC for 1h, then 
homogenized and centrifuged through 25% BSA, the pallet of microvessels was undergone a 
second digestion for 30min and purified via passing through a 70μm size mesh filter.  
 
RNA extraction and microarray analysis. Immortalized human cerebral microvascular 
endothelial cell line (hCMEC/D3) was cultured as described previously (3). Total RNA from 
three biological replicates were isolated using miRNeasy mini kit (Qiagen, Sussex, UK) 
according to the manufacturer’s protocols. Whole EAE and control spinal cords or isolated 
spinal microvessels were homogenized using TRIzol reagent according to the manufacturer’s 
protocols. Total RNA of vessels via LCM was extracted with RNAqueous-micro kit 
following the manufacturer’s protocol (Ambion, Life Technologies Ltd, Paisley, UK). The 
quantity (NanoDrop 1000 spectrophotometer) and the quality (2100 Bioanalyzer, RNA 6000 
Pico LabChip; Agilent, Palo Alto, CA, USA) of the total RNA were analysed. Detailed 
procedures and complete microarray data are available at the Gene Expression Omnibus 
(GEO) under accession number GSE44694 (www.ncbi.nlm.nih.gov/geo). 
 
Quantitative RT-PCR. TaqMan® MicroRNA Reverse Transcription Kit (Applied 
Biosystems, Warrington, UK) was used to synthesise single-stranded cDNA according to the 
manufacturer’s protocol. Briefly, 2.5 ng of total RNA in the case of LCM material and 10 ng 
 8
of total RNA in the case of spinal cords, isolated spinal microvessels or cultured cells were 
used to synthesis single-stranded cDNA. Specific RT and PCR primers for hsa-miR-155 
(000479-4427975), mmu-miR-155 (002571-4427975), hsa-miR-24 (000402-4427975) or 
RNU6B (001093-4440887), internal control, were obtained from Applied Biosystems 
(Warrington, UK). TaqMan® Universal PCR Master Mix (Applied Biosystems, Warrington, 
UK) was used to determine the relative levels of hsa-miRs, mmu-miR1-55 and RNU6B. The 
reaction was then placed in a thermal cycler (DNA engine Opticon 2, Bio-Rad, CA, USA) 
using an initial step at 95 °C for 10 min for activation, followed by 40 cycles (15 s at 95 °C, 
60 s at 60 °C) according to the manufacturer’s protocol. The method 2 -ΔΔCT was used for 
analysis of the data (23). Each control value for each experiment (unstimulated cells, whole 
spinal cords of control mice, microvessels from control human brains or mouse spinal cords) 
was normalized to one and treatment or disease values are always represented as relative to 
control values. SYBR Green real-time PCR (Qiagen, Manchester, UK) was used to determine 
the relative levels of murine claudin-5, (forward) CCTTCCTGGACCACAACATC and 
(reverse) CGCCAGCACAGATTCATACA; pecam-1, (forward) 
GGACGATGCGATGGTGTATAA and (reverse) GCATCACTGTGCATTTGTACTT; gfap, 
(forward) CAGAGGAGTGGTATCGGTCTAA and (reverse) 
GATAGTCGTTAGCTTCGTGCTT; cd45, (forward) CCCTTCTTCTGCCTCAAAGT and 
(reverse) CACCTGGATGATATGTGGTCTC, whereas actin, (forward) 
CTCCCTGGAGAAGAGCTATGA, (reverse) CCAAGAAGGAAGGCTGGAAA, mRNA 
levels were used as an internal control. The method 2 -ΔCT was used for analysis of the data 
(23), results were expressed as relative abundance. 
 
Immunohistochemistry and in situ hybridization. EAE mice in acute phase grade 4 (n = 5) 
and control mice (n = 5) were perfused with 4% paraformaldehyde (PFA) in 0.1M phosphate 
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buffer. After cryoprotection in sucrose and freezing, 15 μm sections of lumbar spinal cords 
were cut onto SuperFrost Plus slides (VWR, Leicestershire, UK). Sections were first treated 
with 2 µg/ml proteinase K in 100mM Tris HCl pH 7.5 and 50 mM EDTA at 37 °C for 10 
min, then fixed again for 5 min in 4% PFA and dehydrated for 5 min in 70% ethanol. 
Sections were prehybridised in hybridisation buffer consisting of 50% formamide, 5x saline 
sodium citrate (SSC), pH 7.0 [20xSSC = 3 M NaCl, 0.3 M tri-sodium citrate] (24), 100 μg/ml 
sheared salmon sperm DNA and 0.1% Tween-20 at the miR probe hybridisation temperature 
(52 °C) for 30 min before replacing this with the hybridisation solution containing probe. 
Double-digoxigenin labelled miRCURY LNA™ probe miR-155 oligonucleotide (5 nM; 
Exiqon, Vedbaek, Denmark) was hybridised with the sections overnight at 52 °C. A similarly 
labelled LNA scrambled oligonucleotide (5 nM) with no complementary sequence in the 
mouse was used as a negative control at the same condition. After hybridisation, sections 
were washed through a series of 5 min SSC washes maintained at 55°C. Sections were 
washed three times with 5xSSC, three times with 1xSSC, and three times in 0.2xSSC. 
Sections were subsequently incubated for 15 min in a blocking buffer consisting of 0.5% 
blocking reagent (Roche, West Sussex, UK) in TBST (100 mM Tris HCl pH 7.5, 150 mM 
NaCl, 0.1% Tween-20) prior to incubation overnight in rat anti-PECAM-1 (1:50, BD 
Biosciences, Oxford, UK) and sheep anti-digoxigenin antibody conjugated with alkaline 
phosphatase (1:1000, Roche West Sussex, UK). Next, sections were washed with TBST four 
times, 5 min each, prior to washing in alkaline development buffer (100 mM Tris HCl pH 
9.5, 100 mM NaCl, 50mM MgCl2, 0.1% Tween-20), and then incubated in NBT/BCIP (1%, 
Roche West Sussex, UK), levamisole (0.5%, Vector Labs, Peterborough, UK) in alkaline 
development buffer at 30°C. After washing with TBST four times, 10 min each, the sections 
were incubated for 1h with secondary goat anti-rat IgG conjugated to Alexa 488 (1:375, 
Zymed Invitrogen, Paisley, UK). Next, sections were washed with TBST four times, 5 min 
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each, before washed in KTBST (50 mM Tris HCl pH 7.5, 150 mM NaCl, 20 mM KCl, 0.5% 
Tween-20) to reduce the background signal in the in situ. Cell nuclei were stained using Dapi 
Fluoromount-G obtained from DouthernBiotech (Alabama, USA). Slides were viewed with 
fluorescent microscope and photographed in colour using a Nikon Eclipse 80i fluorescence 
microscope, a MBF CX9000 digital camera, and PictureFrame software.  
 
Immunocytochemistry. hCMEC/D3 cells were grown to confluence on collagen-coated Lab-
Tek TM multi-well chamber slides. Immunocytochemistry was performed as described 
previously (3). Briefly, hCMEC/D3 cells were fixed for 10 min at room temperature with 4 % 
PFA in PBS pH 7.4. To determine the expression of junctional complex molecules and focal 
adhesions, cells were permeabilized with 0.5% Triton X-100 in PBS for 5 min. Slides were 
blocked with 0.5% BSA for 30 min and incubated with anti-ZO-1 (1:80, Zymed, Paisley, 
UK) and anti-vinculin (1:200, Sigma-Aldrich, Dorset, UK). For talin immunostaining, cells 
were fixed in methanol for 30 min at 4°C followed by cold acetone (maintained at -20°C 
prior to use) for 1min at RT and incubated with anti-talin (1:300, Sigma-Aldrich, Dorset, UK) 
antibody. Cells were washed with PBS and incubated for 1 h at room temperature with a 
secondary goat anti-rabbit or anti-mouse Alexa Fluor 488 (Zymed, Life Technologies 
Invitrogen division, Paisley, U.K.). Slides were viewed with a fluorescent microscope for 
talin and vinculin (Olympus BX61,Olympus, Hertfordshire, UK) or a confocal microscope 
(Leica Microsystems, Mannheim, Germany) for ZO-1 and images captured using Cell^P or 
Leica application suite (LAS) software, respectively. For confocal microscopy, images of 
fifteen Z stacks between 2.5μm in depth were acquired using a 100x oil immersion objective 
and projected onto one image.    
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Ectopic expression of miR-155 and siRNA transfections. hCMEC/D3 cells were seeded and 
grown to 70 % confluence in EGM-2 MV medium before transfection then media was 
changed to EGM-2 MV medium (Lonza, Slough Wokingham, UK) supplemented with the 
following components obtained from the manufacturer: 0.1% (v/v) rhFGF, 0.1% (v/v) 
ascorbic acid, 0.04% (v/v) hydrocortisone and 1.25% (v/v) FBS (hereafter referred to as 
transfection media). To ectopically express miR-155 in hCMEC/D3 cells, 30 nM of pre-miR-
155 and the siPORT Amine transfection agent (Applied Biosystems, Warrington, UK) were 
combined following the manufacturer’s instructions. Inhibition of endogenous miR-155 
expression was performed by transfection with 60 nM of hsa-miR-155 miRIDIAN Hairpin 
Inhibitor (Inhibitor-miR-155). To silence human annexin-2 (ANXA-2), dedicator of 
cytokinesis 1 (DOCK-1), syntenin-1 (SDCBP), and claudin-1 (CLND-1) specific 
siGENOME SMARTpool were used (ThermoFisher scientific, Epsom, UK). In both cases, 
inhibitor-miRs and siRNAs were combined with Lipofectamine 2000 (Invitrogen, Paisley, 
UK) according to the manufacturer’s instructions. For all oligonucleotide, siPORT (pre-
miRs) or lipofectamine 2000 (Inhibitor-miRs or siRNAs) were diluted in Opti-MEM I 
medium (Invitrogen, Paisley, UK) according to the manufacturer’s protocols. The RNA 
oligonucleotide-lipofection agent complexes were then dispensed onto the hCMEC/D3 cells 
and incubated at 37 ºC for 6h (Lipofectamine 2000) or 24h (siPORT Amine). Transfection 
media with oligonucleotide complexes was then replaced with fresh transfection media for 
another 20h (Lipofectamine 2000) or 2h (siPORT Amine). hCMEC/D3 cells were then 
maintained in EGM-2 MV culture media without VEGF until the end of the experiment. 
Non-Targeting scrambled pre-miR, inhibitor-miR or siRNA pool was used as transfection 
control respectively. 
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Lentiviral transduction of 3’ UTR reporter vectors and luciferase assay. The luciferase 
reporter lentiviral vector constructs containing the puromycin resistance gene and the 
Luciferase gene from the firefly Photinus pyralis with the 3’untranslated region (3’UTR) of 
DOCK-1 (Accession number NM_001380), syntenin-1 (Accession number NM_005625), 
annexin-2 (Accession number NM_005625) and claudin-1 (Accession number NM_021101) 
were obtained from Applied Biological Materials Inc. (British Columbia, Canada). 
To generate stable hCMEC/D3 cells a multiplicity of infection of three was used for each of 
the 3’UTR lentiviral constructs. Briefly, hCMEC/D3 cells were seeded to 40% confluence on 
twenty-four well plates. Cells were transduced with transduction media with the following 
components: 1 x 106 transducing units/ml of the lentiviral vector and 8μg/ml of polybrene, all 
suspended in EGM-2 medium. After 12h of transduction, the transduction media was 
removed and fresh EGM-2 medium was added. hCMEC/D3 cells were grown to confluence 
and then split into six well plates. Next, EGM-2 media containing 2μg/ml of puromycin were 
used to select transduced cells. 
Detection of luciferase was performed using Steady-Glo® Luciferase assay system according 
to the manufacturer’s protocol (Promega, Madison, WI, USA). Cells were grown on 
collagen-coated white 96 well cell culture microplates (Greiner bio-one). Luciferase activity 
was detected using a BMG plate reader (Ortenberg, Germany). 
 
Western blot analysis. Cells were lysed by scraping into a lysis solution containing 400μl of 
RIPA buffer (25mM Tris•HCl pH 7.6, 150mM NaCl, 1% NP- 40, 1% sodium deoxycholate, 
0.1% SDS) and a cocktail of inhibitors (5μg/ml of aprotinin, leupeptin, pepstatin and 1mM 
sodium orthovanadate). After sonication, the amount of protein was determined using a 
Biorad DC protein assay (Hertfordshire, UK). Cell lysates were diluted in 1x Laemmli’s 
buffer solution, at 95°C for 10 min. 25μg of total protein was run per lane on 12 and 10% 
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SDS-PAGE gels and transferred onto nitrocellulose membrane (Amersham, 
Buckinghamshire, UK) using wet transfer system (Bio-Rad, Hemel Hempstead, UK). 
Membranes were blocked with 5% non-fat milk/0.05% Tween-20 in PBS for 1h, and 
incubated in the presence of anti-DOCK-1 (1:200, Cell Signaling, Hertfordshire, UK), anti-
syntenin-1 (1:100, AbD Serotec, Oxford, UK), anti annexin-2 (1:3000, BD Biosciences, 
Oxford, UK) and anti-claudin-1 (1:125, Zymed, Paisley, UK) at RT overnight in a humidified 
box and then with a species-specific secondary anti-rabbit IgG (1:3000, Zymed) or anti-
mouse IgG (1:14000, Pierce Biotechnology, Cheshire, UK) antibody conjugated to 
horseradish peroxidase for 1 h at RT. Immunoblots were then developed by enhanced 
chemiluminescence detection (ECL, Amersham, Buckinghamshire, UK). As a control for 
protein loading and transfer, membranes were stripped for 40 min at 50 °C and incubated 
with monoclonal antibody against actin (1:200, Sigma-Aldrich, Dorset, UK) and revealed as 
previously.  
 
In vitro paracellular permeability assays. Cells were seeded onto collagen- and fibronectin-
coated permeable polyester transwell filter inserts (Corning Costar, Buckingham, UK, 0.4μm 
diameter pore, 12mm diameter). hCMEC/D3 cells were grown to 85% confluence and 
transfected as indicated earlier and stimulated for 24h with TNFα and IFNγ (1ng/ml, R&D 
systems, Oxon, UK) or left untreated. Culture media was then removed from the apical 
chamber and 500μl of transport buffer (2% FBS in DMEM without phenol red) containing 
2mg/ml 70kDa or 4kDa was added. The paracellular flux of tracer was performed as 
described previously (3). 
 
In vivo BBB permeability assays. On day 21 after induction of EAE, BBB permeability was 
determined as described previously with modifications (25). Briefly, 70kDa FITC-dextran 
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(250mg/kg) was injected intravenously, 30 min later mice were transcardially perfused with 
0.9% saline (400ml/kg) first and then with 4% PFA (800ml/kg). Lumbar enlargement (L4-5) 
segments were cross-sectioned at 20μm thickness and mounted with DAPI-fluoromount G. 
To determine extravascular intensity of FITC-dextran, images were taken using fluorescent 
microscopy at 40x magnification (Zeiss, Cambridge, UK). Images were quantified with 
ImageJ software and normalized to fluorescence values in liver and to tissue area.  
For the acute model of systemic inflammation, 12 week-old male miR-155-/- or miR-155+/+ 
C57BL/6 mice were injected 2% Evans blue in PBS intraperitoneally at 80 mg/kg. At 18 h, 
lipopolysaccharides (LPS) from Escherichia coli 0111:B4 (4mg/kg, n=6) or PBS alone (n=4) 
were injected intraperitoneally (26). After 6h, blood samples were collected by cardiac 
puncture, mice were perfused with ice cold 0.9% saline and whole spinal cords were flushed. 
Each spinal cord was homogenized in PBS, then mixed with 60% trichloroacetic acid and 
incubated on ice for 30 min, supernatants were collected by centrifugation at 1000g for 30 
min. Absorbances of supernatants and plasma were read at λ 620 nm. Each absorbance value 
was then normalized to fresh weight of spinal cords and to plasma concentration of Evans 
blue. 
 
Statistical analysis. Data are represented as mean ± standard error of the mean (SEM). For all 
experiments, the number of independent experiments, n, is indicated. For miRNA array 
analysis, GeneSpring GX 9 software was used for value extraction. Statistical significance 
was determined by Student’s t test for each miRNA probe. The statistical analysis for the 
mRNA microarray was performed using pairwise comparisons and false discovery rate. 
Statistical significance was considered if P was less than 0.01 as determined by LIMMA 
software. For all other experiments, statistical significance was considered if P was less than 
0.05 as determined by paired, 2-tailed Student’s t test (cultured cells), or by ANOVA 
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(analysis of variance) with posthoc comparisons and Tukey HSD correction on SPSS 
software (animals and human brains). 
 
Results 
MiR-155 is upregulated at the neurovascular unit of MS active lesions 
Our initial investigations started by investigating whether the proinflammatory miR-155 (9) 
was altered at the level of the neurovascular unit in MS active lesions. In order to isolate the 
microvasculature of white matter, we used the laser capture microdissection (LCM) 
technique. We compared miR-155 levels in MS lesions with active, ongoing demyelination 
and inflammation with MS normal appearing white matter (MS-NAWM) and with those in 
white matter of non-neurological disease controls. Clinical information and the 
neuropathological characterization of MS and control tissues used in this study are shown in 
Figure 1A. We observed that MiR-155 at the neurovascular unit in MS lesions was 
significantly increased when compared to MS-NAWM (Fig. 1B) and control-NAWM (data 
not shown). These results suggest that increased levels of miR-155 at the neurovascular unit 
could potentially be implicated in BBB dysfunction in MS. 
 
MiR-155 is differentially regulated during EAE and modulates paracellular 
permeability in vivo 
To examine the temporal expression pattern of miR-155 in vivo, we initially induced EAE in 
Biozzi ABH mice, an animal model of MS, which show a predictable relapsing-remitting 
paralysis course associated with loss of BBB integrity at the spinal cord (20). We observed 
that the expression levels of miR-155 in whole spinal cords did not change at onset of signs 
(EAE-OS, animals with a tail paralysis) (Fig. 2A). However, we observed that miR-155 levels 
were dramatically elevated in acute phase paralysis (APP) animals with hindlimb paralysis 
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and during the recovery phase, reaching levels almost 15 times higher than in control animals 
(Fig. 2A). In addition, miR-155 increased levels were observed in the remission from the 
initial attack and chronic phases following remission from relapses albeit to a lesser extent 
(Fig. 2A). To investigate whether miR-155 was upregulated in the CNS vasculature during 
EAE, we extracted total RNA from isolated spinal cord microvessels. Fig. 2B shows that 
expression of miR-155 in enriched spinal cord microvessels of EAE mice was 25 times 
higher than that of enriched microvessels in control mice using quantitative RT-PCR. 
However, isolated spinal cord microvessels that contain high levels of markers for endothelial 
cells (claudin-5 and cd-31) also show minor amounts of astrocyte (gfap) and leucocyte (cd-
45) markers (Fig. 2C). In order to distinguish the endothelial miR-155 from other CNS 
resident cells or leucocytes, we carried out in situ hybridization in combination with 
immunohistochemistry for endothelial (PECAM-1) marker in spinal cord of EAE APP mice 
(Fig. 2D, 2E). We observed that miR-155 is upregulated in inflamed blood vessel and 
partially co-localizes with endothelial PECAM-1 and Glut-1 expression (Fig. 2F, 2G, 2H, 
Supplementary Fig. 1) but not in their control littermates (Supplementary Fig. 1).  
 
These results lead us to investigate whether the resistance of miR-155-/- mice to develop EAE 
(Fig. 3A) (10, 16) was in part associated with a decrease in vascular leakage at the region of 
inflammation. First, we observed that miR-155+/+ and miR-155-/- mice showed a similar levels 
of leakage to 70kDa FITC-dextran indicating that BBB integrity is maintained in miR-155-/-  
mice (Fig. 3B, 3C). Following induction of EAE, the soluble marker was found to be diffused 
through the spinal cord parenchyma and highly located near to the basolateral domain of 
inflamed blood vessels indicative of BBB breakdown in miR-155+/+ mice (Fig. 3B, 3C). In 
contrast to miR-155+/+ EAE mice, miR-155-/- EAE mice showed a 50% reduction in the BBB 
leakage to the paracellular tracer (Fig. 3B, 3C). However, the reduced BBB leakage observed 
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in miR-155-/- EAE mice may not only be due to a reduction in immune cell activation (9, 27) 
but also in part associated to a decrease in neurovascular dysfunction during 
neuroinflammation.  
In order to investigate the role of miR-155 in inflammation-induced neurovascular 
dysfunction with reduced leucocyte infiltration and/or leucocyte-triggered immune responses 
such as TNFα secretion (Figure 3D), we determined BBB permeability to Evans blue in an 
acute inflammation model induced by intraperitoneal injection of lipopolysaccharide (LPS). 
LPS administration induced a 2-fold increase of Evans blue leakage into spinal cords of miR-
155+/+ mice compared to PBS-treated miR-155+/+ mice (Fig. 3E). By contrast, no increase in 
Evans blue extravasation was observed in miR-155-/- mice spinal cords following LPS 
treatment when compared with PBS-treated miR-155+/+ or miR-155-/- mice (Fig. 3E). Overall, 
these results suggest a potential role of miR-155 at the neurovascular unit in the negative 
modulation of BBB during neuroinflammation. 
 
MiR-155 modulates paracellular permeability of brain endothelium in vitro  
We have shown evidence of increased levels of miR-155 at the neurovascular unit during 
neuroinflammation (Fig. 1B, 2B, 2F, 2G, 2H, Supplementary Fig.1). However, our in vivo 
experiments do not unequivocally exclude indirect effects on neurovascular dysfunction by 
miR-155 expression in other CNS resident cells including astrocytes and pericytes. To better 
understand whether endothelial miR-155 directly mediated barrier dysfunction during 
neuroinflammation, we next investigated whether proinflammatory cytokines altered levels of 
miR-155 in cultured human brain endothelial cells. Indeed, miR-155 was upregulated in 
hCMEC/D3 cell-line by two cytokine treatments including TNFα+IFNγ and TNFα+IL1β but 
not by IFNγ+IL1β (Fig. 4A). Furthermore, we observed a time- and dose-dependent increase 
in miR-155 expression levels in response to TNFα+IFNγ (Fig. 4B). We next investigated 
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whether upregulation of miR-155 was associated with increases in paracellular permeability 
of BEC. hCMEC/D3 cells were transfected with pre-miR-155 (Fig. 4C) and paracellular 
permeability was assayed. First, we observed that low concentrations (1ng/ml) of TNFα and 
IFNγ induced 1.9-fold increase in leakage of fluorescent dextrans across brain endothelial 
monolayers when compared with controls (Fig. 4D). Furthermore, the ectopic expression of 
miR-155 in hCMEC/D3 cells (Fig. 4C) induced a 1.5-fold increase in the leakage of both 
4kDa (data not shown) and 70kDa fluorescent dextrans (Fig. 4D) when compared with 
scrambled pre-miR transfected cells. In contrast, hCMEC/D3 cells transfected with miR-155 
inhibitor (Fig. 4E) partially reversed (by ~40%) the increase in paracellular permeability in 
hCMEC/D3 cells challenged with 1ng/ml of cytokines for 24h (Fig. 4F). These results 
indicate that miR-155 contributes to the cytokine-induced disruption of the paracellular seal 
of brain endothelium, which results in increased paracellular permeability to tracers in vitro.  
 
Over-expression of miR-155 induces changes in the pattern of gene expression of 
hCMEC/D3 cells  
To identify miR-155 target genes in BEC that might be implicated in BBB dysfunction 
relevant to human disease, we then analysed changes in mRNA expression of hCMEC/D3 
cells that overexpress miR-155 using mRNA microarray analysis. We observed that 390 
transcripts (of ~10,600 genes detected) were downregulated by at least ~1.2-fold with a P < 
0.01 significant change by overexpression of miR-155 (GEO accession number GSE44694). 
Using clueGO (28) we observed that the three most statistically significant biological 
processes identified were translation (P<0.01), focal adhesion (FA) (P<0.05) and methionine 
metabolism (P<0.05) (Fig. 5A). Another bioinformatic analytical source, DAVID (29), 
further identified IJC (P<0.05) as a significantly enriched functional category among the 
miR-155-downregulated transcripts in hCMEC/D3 cells.  
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MiR-155 induces reorganization of focal adhesions and tight junctions in hCMEC/D3 
cells 
Since genes involved in FA were remarkably over represented in the set of genes 
downregulated by over expression of miR-155 in hCMEC/D3 cells, we investigated whether 
FA organization was affected by modulation of miR-155 levels using immunocytochemical 
techniques. Two structural components of FA, vinculin and talin, showed a characteristic 
staining pattern of FA, manifested by the presence of flat and elongated structures located 
centrally and near the cell periphery, in hCMEC/D3 cells transfected with scrambled pre-miR 
(Fig. 5B, 5C). In addition, vinculin immunostaining was also shown to be highly localised at 
the cell-cell junctions as shown by the belt-like staining pattern on the cell periphery (Fig. 
5B). 
 
Following transfection with pre-miR-155, vinculin immunostaining located centrally in 
hCMEC/D3 cells did not appear to be affected (Fig. 5B). However, we observed a remarkable 
reduction in the staining of vinculin located at the cell-cell junctions (Fig. 5B). Ectopic 
expression of miR-155 also altered talin sub-cellular distribution located centrally and at cell 
borders (Fig. 5C). TNFα and IFNγ-treatment induced a change in the cell morphology 
characterized by elongation of the cell shape accompanied by a reorganization of vinculin 
towards a more centrally localised and punctuate pattern (Fig. 5B). Inhibition of cytokine-
induced increase in miR-155 levels by miR-155 inhibitor partially rescued vinculin (Fig. 5B), 
but not talin (Fig. 5C), delocalization at the cell-cell junctions.   
 
We also observed that ZO-1 showed a continuous intercellular junction pattern at the cell 
borders in hCMEC/D3 cells transfected with scrambled pre-miR and in untransfected cells 
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(Fig. 5D). By contrast, over expressing miR-155 in BEC induced ZO-1 reorganization, 
characterized by disruption of its normal distribution from the cell-cell boundaries, similarly 
to the effect of cytokines on junctional organization (Fig. 5D). Furthermore, cytokine-induced 
redistribution of ZO-1 (Fig. 5D) was partially prevented by miR-155 inhibitor (Fig. 5D). 
Altogether, these results led us to investigate the putative target genes involved in miR-155-
induced changes in FA and IJC organization that might contribute to alterations in the 
permeability of BEC. 
 
Bioinformatic analysis and paracellular permeability assays identify four miR-155 
putative targets associated with barrier dysfunction in hCMEC/D3 cells 
Using TargetScan5.0 (8), we identified 63 putative target genes with a seed match for miR-
155 that were downregulated by over expression of miR-155 at the mRNA level in 
hCMEC/D3 cells (Fig. 6A, Supplementary Table 1). In order to further select candidate genes 
associated with the increased paracellular permeability induced by miR-155 in BEC, we used 
additional criteria by only including genes associated with cell-cell junctions and/or the 
integrin adhesome (30-32) and those that were experimentally validated by 3’UTR reporter 
assays in other cell types (12, 13, 33). Using this strategy, we identified seven candidate 
genes including four components of FA, dedicator of cytokinesis 1 (DOCK-1), syntenin-1 
(SDCBP), palladin (PALLD), integrin alpha-V (ITGAV) and three IJC molecules, annexin-2 
(ANXA-2), claudin-1 (CLDN-1), and prion protein (PRNP) (Fig. 6B). 
 
We then observed that reducing the expression of the FA components DOCK-1 and syntenin-
1 induced a 1.4 fold increase in the paracellular permeability when compared with control 
(Fig. 7A). This effect was associated with delocalization of both ZO-1 and vinculin from the 
cell borders (Fig. 7B). Similarly, silencing claudin-1 and annexin-2 induced a 1.5 fold 
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increase in paracellular permeability when compared with controls (Fig. 7A). Silencing of 
claudin-1 also induced disassembly of ZO-1 from the cell borders (data not shown). Silencing 
of the remaining three candidate genes, palladin, integrin alpha-V and prion protein, did not 
induce an increase in the paracellular permeability of hCMEC/D3 cells (data not shown). 
 
We next validated the regulatory roles of miR-155 in FA and IJC using luciferase reporter 
assay. Results showed that miR-155 overexpression in hCMEC/D3 cells decreased luciferase 
activity by approximately 30 to 40% in cells carrying 3’UTR of DOCK-1, syntenin-1, 
annexin-2 or claudin-1 when compared with scrambled pre-miR controls (Fig. 7C). These 
results were further supported by a decrease in the protein levels of DOCK-1 (~65%), 
syntenin-1 (~50%), annexin-2 (~30%) or claudin-1 (~50%) in hCMEC/D3 cells 
overexpressing miR-155 as evidenced by immunoblotting (Fig. 7D, 7E). These results 
demonstrate that four target genes for miR-155 including two components of FA, DOCK-1, 
syntenin-1, and two components of IJC, annexin-2 and claudin-1, modulate brain endothelial 
permeability and potentially mediate, at least partially, miR-155-induced BBB breakdown 
during inflammation.  
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Discussion  
We propose that miR-155 acts as a novel negative regulator of BBB function during 
neuroinflammation by modulating brain endothelial cell-to-cell and cell-to-matrix 
interactions, thereby contributing to the pathogenesis of CNS neuroinflammatory disorders 
such as MS. The general consensus is that miR-155 is a proinflammatory miRNA (9) and that 
it might participate in the harmonization of cell activation during inflammatory processes in 
mammals. Consistent with this proposal, recent work has shown that miR-155 is highly 
expressed in active inflammatory MS plaques where astrocytes were identified as one of the 
potential cellular sources of this miRNA (15). Our results further suggest that miR-155 is 
highly expressed at the neurovascular unit during MS active lesion and is differentially 
upregulated in mouse whole spinal cords at different stages of EAE. Indeed, we used an 
animal model that show a reproducible and predictable relapsing-remitting EAE (20). During 
EAE-OS there is an infiltration of leucocytes and BBB leakage (20) without any significant 
changes in miR-155 levels in whole spinal cords. This suggests that the cellular source of 
miR-155 at this stage might be low and/or difficult to be detected if the increase in miR-155 
is restricted to a few affected areas of the neurovascular unit. However, miR-155 levels are 
rapidly upregulated during paralysis in initial acute attack (APP) at a time when maximal cell 
infiltration is occurring around the vasculature (20). Furthermore, in this EAE model the 
recovery occurs when the animals begin to gain weight and clinical scores subside (20). This 
is accompanied by a gradual recovery of BBB function and reduction of cellular infiltration 
of the CNS (20), but we did not observe a decrease in the pro-inflammatory miR-155 levels. 
This result suggested that the proinflammatory cytokine profile at this stage was still high. It 
is tempting to speculate that activation mechanisms that initiate the resolution of the 
inflammatory response during the recovery phase might also be able to desensitize the 
neurovascular unit to the effects of miR-155, before any decrease in miR-155 levels are 
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observed by an unknown molecular mechanism. This may also be the case in the first 
remission phase when inflammatory lesions resolve and BBB dysfunction is minimal but 
miR-155 levels are still elevated (20). Another cellular sources of miR-155 in EAE spinal 
cords might be from activated leucocytes since mononuclear cells including T lymphocytes 
with increased miR-155 levels infiltrate the CNS parenchyma in EAE (10, 16). However, 
increased miR-155 levels at the neurovascular unit were observed in isolated microvessels of 
EAE spinal cords. We also observed by in situ hybridization that during neuroinflammation 
miR-155 appeared to be expressed in the microvasculature as well as in large blood vessels 
including venules. 
 
Previous studies have shown that BBB breakdown is a fundamental event during the course 
of MS and that the magnitude of the neurovascular dysfunction in EAE is associated with the 
neurological severity of the disease (34). Furthermore, mice deficient in bic/miR-155 gene 
showed partial resistance to develop EAE in this and previous studies (10, 16) and here we 
show that loss of miR-155 plays a protective role against BBB leakage at the region of 
inflammation. In addition, using LPS as an acute model of systemic inflammation with 
reduced leucocyte infiltration and circulating TNFα response, we observed that loss of miR-
155 attenuated the increase of BBB permeability. However, these in vivo experiments are not 
conducive to unequivocally exclude the effect of miR-155 in other CNS resident cells, 
astrocytes and pericytes, during neurovascular inflammation. To test the hypothesis that brain 
endothelial miR-155 is involved in BBB dysfunction, we examined the effects of miR-155 on 
brain endothelial barrier functions in cell culture. Brain endothelial miR-155 is upregulated 
by proinflammatory cytokines in a time- and dose-dependent manner, an effect that coincides 
with cytokine-mediated brain endothelial barrier permeability (3). Moreover, our result show 
that ectopic expression of miR-155 mimicked cytokine-induced increase in permeability 
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whereas knockdown of endogenous miR-155 partially prevented cytokine-induced barrier 
disruption in BEC, indicating an active role for endothelial miR-155 in inflammation-induced 
BBB breakdown. Hence, miR-155 appears to be a pro-inflammatory miRNA, but it is 
induced by inflammation and/or infection at early times suggesting that it contributes to the 
early stages of inflammation at the neurovascular unit. 
 
The mechanism by which miR-155 may exacerbate the breakdown of BBB appears to 
involve two different cellular pathways. First, miR-155 may be an important “control node” 
for the expression of IJC molecules in brain endothelium, thereby directly affecting the 
organization of cell-cell junctions. Consistent with our results Kong et al. reported that miR-
155 induced delocalization of ZO-1 from the cell-cell contacts in tumorigenic epithelial cells 
(35). In this study, we identified that miR-155 may modulate BEC permeability and tight 
junction (TJ) organization, by directly targeting components of IJC, claudin-1 and annexin-2. 
Claudin-1, a target for miR-155, has an important barrier function at least in epithelial cells 
(36) although its expression by BEC in vivo is controversial (37). Recently, it has been shown 
that ectopic expression of claudin-1 in C57BL/6 mice prevents BBB leakiness in EAE 
animals as compared with littermate controls (32). Furthermore, loss of claudin-1 at the BBB 
has also been associated with barrier dysfunction in glioblastoma multiforme (38) and 
hepatitis C infection (39). In addition, annexin-2, another miR-155 target, has also been 
shown to regulate endothelial cell morphology and junctional integrity via its association with 
VE-cadherin (31). However, little is known about the contribution of annexin-2 to 
strengthening the BEC barrier. Here we have shown that silencing of annexin-2 expression 
has significant consequences for BEC barrier function at least in vitro. Hence, miR-155 direct 
targeting of at least two components of CNS interendothelial junctional complexes may lead 
to increased BBB permeability. 
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A second cellular pathway modulated by endothelial miR-155 involves FA organization, 
which may also lead to increased BBB permeability following a cytokine stimulus. We 
observed that miR-155 affects the distribution of vinculin and talin in BEC suggesting 
alterations in the cellular attachment to their matrix substrate. Vinculin is a cytoskeleton-
associated protein and plays an important role in FA assembly and strength (40). Talin, 
another FA molecule, directly interacts with the cytoplasmic tail of ß-integrins inducing their 
activation (41). Indeed, β1-integrin-mediated adhesion of BEC to the surrounding ECM has 
been recently shown to be critical for stabilizing claudin-5 in tight junctions and for BBB 
integrity (42). Here, we observed that miR-155 has the capacity to directly target FA 
components in BEC and that downregulation of at least some of these components may lead 
to increased BEC permeability. For instance, DOCK-1 forms part of focal contacts and 
participates in the downstream integrin signal transduction pathway by forming complexes 
with engulfment and cell motility (ELMO) protein (43). It is possible that the DOCK-1-
ELMO complex, a guanine nucleotide exchange factor, might regulate endothelial 
permeability by modulating the activity of Rho-family GTPases such as Rac-1 although this 
does not exclude the possibility that FA disassembly may directly lead to increased BEC 
permeability (44). Indeed, another focal adhesion molecule that we found to be regulated by 
miR-155 in cultured BEC is syntenin-1, an adaptor and scaffold protein that contains PDZ 
(postsynaptic density protein-95, postsynaptic discs large, and zona occludens-1) motifs. 
Initially, syntenin-1 was shown to interact with syndecans, heparan sulfate proteoglycans that 
assist cell adhesion and promote attraction and concentration of growth factors at the cell 
surface (45). It has also been shown that knockdown of syntenin-1 prevents fibronectin-
induced formation of integrin ß1/FAK/c-Src complex, which may play an important role in 
the downstream focal contact signalling pathway (46). Therefore, it appears that not only 
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structural FA proteins are important for stabilizing TJs and the brain endothelial barrier but 
also FA adaptor and signaling proteins. While in other cell types such as fibroblasts (47), 
miR-155 may promote migration by silencing genes implicated in modulating cell-to-matrix 
attachment, endothelial miR-155 may indirectly contribute to increased BBB permeability via 
targeting FA components.   
 
In conclusion, we propose that miR-155 modulates key features of the brain endothelial 
barrier during inflammation and might play an important role during the pathogenesis of CNS 
inflammatory disorders that affect BBB. In addition, endothelial miR-155 may be acts as an 
effector of inflammatory mediators associated with promotion of inflammation and 
subsequent barrier breakdown. Here we demonstrate that miR-155 might contribute to BBB 
breakdown during neuroinflammation by altering the phenotype and function of 
neurovascular endothelium, in particular components of cell-to-cell and cell-to-matrix 
adhesion pathways, thereby revealing potential therapeutic targets to ameliorate for CNS 
inflammatory disorders. 
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Figure legends  
Figure 1. MiR-155 is induced in active lesions of MS patients. A, Demographic and clinical 
characteristics of MS and control brain samples used in the study. NA= not applicable, NIA= 
no information available. B, Laser capture microdissection was used to isolate cerebral blood 
vessels from active lesions of multiple sclerosis patients (MS-AL) and normal appearing 
white matter of MS patients (MS-NAWM), and total RNA was then extracted. MiR-155 
expression levels were determined by quantitative RT-PCR. U6B small nuclear RNA was 
used as an internal standard. 
 
Figure 2. MiR-155 is induced in spinal cords of EAE mice. A, EAE was induced in Biozzi 
ABH mice using spinal cord homogenates, and total RNA from spinal cords at different 
clinical status (OS, onset of signs; APP, acute phase paralysis; Recovery; Remission; 
Chronic) were used to determine levels of miR-155 by quantitative RT-PCR. U6B small 
nuclear RNA was used as an internal standard. *P<0.05, **P<0.01, ***P<0.001 compared to 
their normal littermate controls (n=6). B, Total RNA from isolated spinal cord microvessels 
in EAE APP mice and in their control littermates were used to determine miR-155 levels by 
quantitative RT-PCR. Microvessels from the spinal cord of 3 mice were pooled and analyzed 
as one sample. Data represent the mean ± SEM, **P<0.01, compared to their normal 
littermate controls (n=3). C, Total RNA in B were used to determine brain endothelial cell 
(claudin-5 and pecam-1), astrocytes (gfap) and leucocyte (cd-45) markers by quantitative 
RT-PCR. D and E, hematoxylin and eosin staining of a spinal cord from EAE APP mice. 
Immune-cell infiltration is illustrated at higher magnification in E. Scales bar in D is 500 μm 
and in E is 50 μm. F, G and H, In situ hybridization for miR-155 combined with 
immunohistochemistry to identify PECAM-1+ cells in EAE mouse spinal cord. (F) In the 
bottom left panel, DAPI labels nuclei and a white arrow shows nucleus of a brain endothelial 
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cell. The upper left panel shows expression of miR-155 (black arrow) and a higher 
magnification is shown in G. The bottom right panel shows immunostaining of the 
endothelial specific marker PECAM-1 (white arrow). A merged image (upper right panel) 
demonstrates co-localization of miR-155 and PECAM-1 (black arrows) and a higher 
magnification is shown in H. APP, EAE ABH mouse at acute stage with a clinical score of 4. 
Scale bar, 25μm.  
 
Figure 3. Inflammation-induced BBB breakdown is partially prevented in miR-155-/- mice. 
EAE was induced in miR-155+/+ and miR-155-/- mice using Hooke Kit™ MOG35-55/CFA 
Emulsion PTX. A, Deletion of miR-155 ameliorates EAE. * Two way ANOVA test of 
clinical score of all the time points demonstrated significant difference between the two 
groups. Data presented as mean ± SEM (n = 10 for each group). B, At day 21 after induction, 
mice were injected intravenously with 70kDa FITC-dextran (250mg/kg), and lumbar spinal 
cords and livers were taken after perfusion with fixative. Images of cross sections of spinal 
cords at lumbar 4-5 levels were analyzed to determine extravascular fluorescence intensity. 
(B) Representative images show control non-immunized miR-155+/+ and miR-155-/- mice, or 
immunized miR155+/+ and miR-155-/- EAE mice. Scale bar, 25μm. C, Quantification of 
extravascular intensity of 70kDa FITC-dextran. For each mouse, the fluorescence intensity of 
spinal cord sections was normalized to that of liver sections from the same animal. *P<0.05 
compared with non-immunized miR-155+/+ and miR-155-/- mice or immunized miR-155-/- 
EAE mice by ANOVA with post-hoc comparisons and Tukey HSD correction. Error bars 
represent SEM (n=10). D, Plasma levels of TNFα in WT and miR-155-/- mice 6 h after 
intraperitoneal injection of LPS (4mg/kg) assessed by ELISA. Values are represented as fold 
change of LPS-treated WT and LPS-treated miR-155-/- mice relative to those in PBS-treated 
WT (5.03±0.85pg/ml) and PBS-treated miR-155-/- (4.21±0.37pg/ml), respectively. Error bars 
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represent SEM (n=4 for PBS group, n=6 for LPS group). E, Quantification of efflux of Evans 
blue in the spinal cords of mice as in D. *P<0.05 compared with PBS (vehicle) injected miR-
155+/+ and miR-155-/- mice or with LPS injected miR-155-/- mice by ANOVA with post-hoc 
comparisons and Tukey HSD correction. Error bars represent SEM (n=4 for PBS group, n=6 
for LPS group). 
 
Figure 4. MiR-155 contributes to cytokine-induced brain endothelial barrier breakdown in 
vitro. A, Total RNA was isolated from hCMEC/D3 cells treated with TNFα and IFNγ or 
TNFα and IL1β or IL1β and IFNγ to determine miR-155 levels by quantitative RT-PCR. 
MiR-24 is an example of miRNA that did not change following cytokines treatment. U6B 
small nuclear RNA was used as an internal standard. Data represent the mean ± SEM, 
**P<0.01 compared to unstimulated cells (n=3). B, Confluent monolayers of hCMEC/D3 
cells were stimulated with TNFα and IFNγ at 1, 10 and 100 ng/ml for 24 h or treated with 
TNFα and IFNγ (100ng/ml) at 2, 6 and 24h to determine miR-155 levels by quantitative RT-
PCR. Control values were normalized to one and results are expressed as miRNA levels in 
TNFα and IFNγ-treated cells relative to those in unstimulated cells. Data represent the mean 
± SEM, *P<0.05, **P<0.01 compared to unstimulated cells (n=3). C, MiR-155 expression 
levels in hCMEC/D3 cells treated with TNFα and IFNγ (1ng/ml) or transfected with pre-miR-
155 (30nM) for 24 h. Values are represented as miRNA levels relative to those in control 
cells or in cells transfected with scrambled pre-miR, respectively. U6B small nuclear RNA 
was used as an internal standard. *, # P<0.05 compared to *vehicle or #scrambled pre-miR 
transfected cells, respectively. Data represent the mean ± SEM (n=3). D, The brain 
endothelial permeability coefficient (Pe) for 70kDa FITC dextran was measured in cells 
transfected with pre-miR-155 or stimulated with TNFα and IFNγ as in C. Data represent the 
mean ± SEM and *, #P<0.05 compared to *vehicle or #scrambled pre-miR transfected cells, 
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respectively (n=3). E, MiR-155 levels were analyzed in hCMEC /D3 cells transfected with 
scrambled miR inhibitor (60nM) or miR-155 inhibitor (60nM) in the presence and absence of 
TNFα and IFNγ (1ng/ml) for 24 h. U6B RNA was used as an internal standard. Data 
represent the mean ± SEM (n=3). #P<0.05 compared to scrambled miR inhibitor-transfected 
cells. F, Permeability coefficient (Pe) for 70kDa FITC dextran was measured in hCMEC /D3 
cells transfected with scrambled miR inhibitor or miR-155 inhibitor in the presence and 
absence of TNFα and IFNγ as in E. Data represent the mean ± SEM and *,#P<0.05 compared 
to *basal scrambled miR inhibitor-transfected cells. or #cytokine-treated scrambled miR 
inhibitor-transfected cells (n=3). 
 
Figure 5. MiR-155 induces changes in the pattern of gene expression of junctional molecules 
in hCMEC/D3 cells and alters their subcellular distribution. A, A list of genes with 
downregulated mRNA transcripts following ectopic expression of miR-155 in hCMEC/D3 
cells, determined by microarray analysis, was used to create a pie visualization map with 
KEGG, Biocarta and GO molecular functions by the ClueGO bioinformatic tool (28) (The 
full data analysis of mRNA transcripts altered by overexpression of miR-155 in hCMEC/D3 
cells can be accessed in GEO with accession number GSE44694). B, C and D, hCMEC/D3 
cells were transfected with either pre-miR-155, or miR-155 inhibitor prior to addition of 
TNFα and IFNγ (1ng/ml) for 24h. (B) Vinculin and (C) talin were used as focal adhesion 
markers and visualized by immunofluorescence. In untransfected or scrambled pre-miR-
transfected hCMEC/D3 cells, vinculin and talin staining pattern was located centrally and at 
the cell borders. Over expression of miR-155 induced the disappearance of vinculin primarily 
from the cell borders whereas talin was delocalized both from the cell borders and centrally. 
TNFα and IFNγ induced reorganization of both vinculin and talin in hCMEC/D3 cells, but 
only vinculin delocalization was partially prevented by miR-155 inhibitor. Images are 
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representative of three separate experiments. Scale bar, 20μm. (D) Arrow heads show ZO-1 
immunostaining in hCMEC/D3 cells characteristic of TJs discerned by continuous staining at 
the cell borders (arrowheads). The arrows show that miR-155 overexpression or TNFα and 
IFNγ stimulus for 24h induced ZO-1 fragmentation from the cell to cell contacts compared 
with cells transfected with scrambled pre-miR or treated with vehicle. Knockdown of miR-
155 using miR-155 inhibitor partially prevented cytokine-induced disassembly of ZO-1 as 
indicated by arrowheads (Bottom right). Images are representative of four separate 
experiments. Scale bars, 25μm.   
 
Figure 6. MiR-155 predicted targets in hCMEC/D3 cells. hCMEC/D3 cells were transfected 
with pre-miR-155 or with scrambled pre-miR as a control. RNA was extracted and analyzed 
using microarray profiling. hCMEC/D3 cells expressed ~10,600 genes out of ~24,000 genes 
tested. A, Two-way Venn diagram of genes downregulated by ectopic expression of miR-155 
and putative predicted targets for miR-155 expressed by hCMEC/D3 cells. Sixty three genes 
where identified to have target sites for miR-155 and downregulated after ectopic expression 
of miR-155 in hCMEC/D3 cells. B, Table showing seven candidate genes involved in miR-
155-induced barrier breakdown in hCMEC/D3 cells. Criteria for selection: 1) Genes 
downregulated at the mRNA levels by ectopic expression of miR-155 (The full data analysis 
of mRNA transcripts altered by overexpression of miR-155 in hCMEC/D3 cells can be 
accessed in GEO with accession number GSE44694); 2) Genes with function related to cell-
cell or cell-matrix adhesion; 3) miR-155 predicted targets as identified by databases 
(Targetscan) and/or experimentally validated by 3’ UTR-reporter assays in other cell types 
(12, 13, 33). 
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Figure 7. MiR-155 silences genes associated with cell-cell and cell-matrix junctions leading 
to increased paracellular permeability in hCMEC/D3 cells. A, Silencing of DOCK-1, 
syntenin-1, annexin-2 or claudin-1 using specific siRNAs induced an increase in hCMEC/D3 
cells paracellular permeability to FITC-dextran. *P<0.05, **P<0.01 compared to non-target 
siRNA negative control. Error bars represent SEM (n=3 or 4). B, Silencing of DOCK-1 or 
syntenin-1 using specific siRNAs induced delocalization of ZO-1 and vinculin from the cell 
periphery denoted by arrows. Images are representative of three separate experiments. Scale 
bar, 20μm. C, Cells were transiently transfected with pre-miR-155 or scrambled pre-miR in 
hCMEC/D3 cells stably expressing luciferase constructs with the 3’ UTR of the indicated 
genes. Ectopic expression of miR-155 reduces luciferase activity for each construct. Data 
represente mean ± SEM (n=3). *P<0.05 compared to scrambled pre-miR-transfected cells. D, 
DOCK-1, syntenin-1, annexin-2 and claudin-1 protein levels were determined using Western 
blot analysis in hCMEC/D3 cells transfected with scrambled pre-miR or pre-miR-155. The 
same blots were reprobed with anti-actin antibody as indicated for each gene. E, Protein 
expression levels in D were quantified using ImageJ software and presented as mean ± SEM 
(n=3). *P<0.05 compared to scrambled pre-miR-transfected cells. 
 
 
 







Supplementary information. 
Supplementary Methods. 
Laser capture microdissection of microvessels in human brain sections 
Laser capture microdissection (LCM) was used to isolate microvessels from active 
lesions and normal appearing white matter of MS brains and from white matter of 
control brains using a rapid staining protocol. Briefly, frozen sections of 10 μm 
thickness were mounted on uncoated slides. Next, the tissue was fixed in cold acetone 
(maintained at 4 °C) for 3 min at RT. Sections were air-dried for 1 min and rapidly 
stained using toluidine blue solution for 1 min at RT. To eliminate the excess of 
toluidine blue staining, slides were rinsed in diethyl pyrocarbonatetreated deionized 
water and dehydrated in a graded series of ethanol [70 %, 80 %, 90 % and 100 %; 
(v/v)] for 10 s in each solution. Slides were finally cleared in xylene for 1 min and air-
dried at RT. Approximately 200 blood vessels were isolated from each case using 
PixCell II laser capture microdissection system (Arcturus BioScience, Mountain 
View, CA, USA) and LCM-caps (Applied Biosystems, Warrington, UK). 
 
Immunohistochemistry and in situ hybridization 
Sections were incubated with primary antibodies rabbit anti-GLUT-1 1:100 (Merck-
Millipore, Billerica, USA) in phosphate buffer saline (PBS). After washing with PBS, 
sections were incubated for 4 h with secondary goat anti-rat IgG conjugated to Alexa 
Fluor 555 (1:400, Zymed Invitrogen, Paisley, UK).  
 
 
 

Table S1. Targetscan predicted mRNA targets for miR-155 expressed by hCMEC/D3 cells 
and their regulation by transfection with pre-miR-155 
PROBE_ID ACCESSION SYMBOL logFC ADJ.P.VAL 
ILMN_2324421 NM_182743.1 TXNRD1 -0.557288085 1.7E-05 
ILMN_1703178 NM_003469.3 SCG2 -0.55585154 5.8E-03 
ILMN_1724789 NM_000611.4 CD59 -0.504459026 6.3E-05 
ILMN_1711899 NM_001002857.1 ANXA2 -0.460048158 4.2E-05 
ILMN_1756501 NM_003032.2 ST6GAL1 -0.453081161 1.3E-03 
ILMN_1717056 NM_001093771.1 TXNRD1 -0.44765833 1.1E-04 
ILMN_1724686 NM_021101.3 CLDN1 -0.441355452 1.8E-04 
ILMN_1783753 NM_015913.2 TXNDC12 -0.432370657 8.1E-05 
ILMN_1733519 NM_005342.2 HMGB3 -0.413917585 1.2E-04 
ILMN_1708016 NM_080821.2 C20orf108 -0.408461489 3.3E-04 
ILMN_1769245 NM_006851.2 GLIPR1 -0.405515942 1.7E-04 
ILMN_2075189 NM_017515.3 SLC35F2 -0.403517113 1.7E-04 
ILMN_2360415 NM_183079.2 PRNP -0.380844048 3.3E-04 
ILMN_2094061 NM_014214.1 IMPA2 -0.377501495 2.1E-04 
ILMN_1671891 NM_017933.3 PID1 -0.375489786 7.5E-04 
ILMN_1769810 NM_006407.3 ARL6IP5 -0.375087151 8.5E-04 
ILMN_1738383 NM_001961.3 EEF2 -0.374106404 8.5E-04 
ILMN_1755937 NM_001002857.1 ANXA2 -0.372886212 3.1E-04 
ILMN_2363586 NM_001007067.1 SDCBP -0.362052767 1.9E-03 
ILMN_1703060 NM_181519.2 SYT15 -0.354872236 1.4E-03 
ILMN_1747160 NM_181519.2 SYT15 -0.345640411 1.3E-02 
ILMN_1737988 NM_001080121.1 PRNP -0.344880142 1.1E-03 
ILMN_1667893 NM_022748.10 TNS3 -0.342774133 4.1E-03 
ILMN_2169439 NM_002210.2 ITGAV -0.340768976 1.3E-03 
ILMN_1688622 NM_013438.3 UBQLN1 -0.340732475 7.1E-04 
ILMN_2357062 NM_134470.2 IL1RAP -0.338724286 7.1E-04 
ILMN_1715789 NM_001380.3 DOCK1 -0.331196893 9.3E-04 
ILMN_2117508 NM_138455.2 CTHRC1 -0.329325946 3.7E-03 
ILMN_2316236 NM_139212.2 HOPX -0.327274253 1.4E-03 
ILMN_1746013 NM_004598.3 SPOCK1 -0.326242908 6.1E-03 
ILMN_2320906 NM_006054.2 RTN3 -0.325939304 6.0E-03 
ILMN_1729058 NM_004866.4 SCAMP1 -0.320643608 1.4E-03 
ILMN_1708414 NM_019067.4 GNL3L -0.320346284 3.1E-03 
ILMN_1780236 NM_002676.1 PMM1 -0.317074346 6.4E-03 
ILMN_2063586 NM_013943.1 CLIC4 -0.311878207 6.3E-03 
ILMN_1671250 NM_013943.1 CLIC4 -0.308082947 5.2E-03 
ILMN_1671404 NM_003174.3 SVIL -0.301320871 2.7E-03 
ILMN_1688753 NM_014754.1 PTDSS1 -0.300595598 4.3E-03 
ILMN_2082244 NM_001037165.1 FOXK1 -0.300532441 2.5E-03 
ILMN_1682738 NM_005902.3 SMAD3 -0.297799425 4.0E-03 
ILMN_1707077 NM_002959.4 SORT1 -0.296641009 1.9E-03 
ILMN_1804277 NM_152594.1 SPRED1 -0.296399448 2.7E-03 
ILMN_1769191 NM_016592.2 GNAS -0.296272717 1.6E-03 
ILMN_1769191 NM_016592.2 GNAS -0.296272717 1.6E-03 
ILMN_1736704 NM_001037954.2 DIXDC1 -0.294865454 4.4E-03 
ILMN_1743714 NM_014550.3 CARD10 -0.29450325 5.6E-03 
ILMN_2393763 NM_001024960.1 ARPC4 -0.291570641 4.4E-03 
ILMN_1766169 NM_005504.4 BCAT1 -0.289374644 4.8E-03 
ILMN_1651347 NM_014755.1 SERTAD2 -0.288753138 2.7E-03 
ILMN_2176768 NM_012247.3 SEPHS1 -0.286872143 8.6E-03 
ILMN_1788701 NM_033222.2 PSIP1 -0.284419562 5.5E-03 
ILMN_1751097 NM_194071.2 CREB3L2 -0.280735738 2.9E-03 
ILMN_1679796 NM_014765.1 TOMM20 -0.280336735 3.5E-03 
ILMN_1769517 NM_001081640.1 PRKDC -0.278718443 5.9E-03 
ILMN_1720965 NM_001007466.1 TULP4 -0.27835712 7.8E-03 
ILMN_2272876 NM_031912.3 SYT15 -0.276205853 8.7E-03 
ILMN_1737184 NM_031942.4 CDCA7 -0.272470028 4.0E-03 
ILMN_1698323 NM_001031706.1 PLEKHB2 -0.267386789 7.1E-03 
ILMN_2374865 NM_001040619.1 ATF3 -0.267156301 7.3E-03 
ILMN_1779886 NM_020773.1 TBC1D14 -0.262649064 7.7E-03 
ILMN_2253648 NM_006904.6 PRKDC -0.260542479 1.9E-02 
ILMN_1727194 NM_001219.2 CALU -0.25793313 8.2E-03 
ILMN_1698732 NM_016081.3 PALLD -0.244394702 7.7E-03 
ILMN_1719972 NM_017514.2 PLXNA3 -0.23564954 8.2E-03 
ILMN_2157951 NM_005819.4 STX6 -0.235620546 8.2E-03 
ILMN_2188264 NM_001554.3 CYR61 -0.235507217 9.9E-03 
ILMN_1800634 NM_005009.2 NME4 -0.230180068 9.9E-03 
ILMN_2375830 NM_001037954.2 DIXDC1 -0.22456104 1.8E-02 
ILMN_2337740 NM_020245.3 TULP4 -0.212661064 3.2E-02 
ILMN_2363065 NM_201430.1 RTN3 -0.2083027 2.7E-02 
ILMN_2297710 NM_017958.1 PLEKHB2 -0.194937569 3.2E-02 
ILMN_2313821 NM_145813.1 AIFM1 0.259641014 4.9E-03 
 
